Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$2.21
+7.3%
$1.49
$1.03
$2.57
$442.75M1.221.59 million shs3.42 million shs
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
$3.88
+1.8%
$3.75
$2.60
$7.77
$220.26M1.77186,045 shs120,580 shs
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
$5.78
-9.0%
$5.39
$3.90
$14.67
$410.89M1.37659,528 shs1.17 million shs
Rallybio Co. stock logo
RLYB
Rallybio
$0.32
-2.8%
$0.38
$0.22
$1.73
$13.32M-1.28112,823 shs58,596 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
0.00%+11.96%+41.10%+19.77%+27.95%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.00%+7.93%-1.80%-16.99%-12.61%
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
0.00%+23.54%+24.51%-21.41%-25.73%
Rallybio Co. stock logo
RLYB
Rallybio
0.00%-5.10%+8.57%-52.96%-78.89%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
2.2871 of 5 stars
3.71.00.00.02.52.50.6
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
0.5367 of 5 stars
1.00.00.00.03.22.50.6
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
4.3328 of 5 stars
4.52.00.04.32.11.70.6
Rallybio Co. stock logo
RLYB
Rallybio
2.1454 of 5 stars
3.03.00.00.01.61.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
3.33
Buy$8.67292.16% Upside
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
2.00
Hold$4.003.09% Upside
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
3.00
Buy$19.17231.60% Upside
Rallybio Co. stock logo
RLYB
Rallybio
2.00
Hold$10.003,025.00% Upside

Current Analyst Ratings Breakdown

Latest RLYB, ATAI, DSGN, and ORIC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/20/2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$5.00
5/20/2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/13/2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/6/2025
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$15.00 ➝ $12.00
5/6/2025
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight
5/5/2025
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$21.00 ➝ $21.00
4/15/2025
Rallybio Co. stock logo
RLYB
Rallybio
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
4/13/2025
Rallybio Co. stock logo
RLYB
Rallybio
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/9/2025
Rallybio Co. stock logo
RLYB
Rallybio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
4/8/2025
Rallybio Co. stock logo
RLYB
Rallybio
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
3/20/2025
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$20.00
(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
$1.86M237.65N/AN/A$1.47 per share1.50
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/A$4.96 per shareN/A
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
N/AN/AN/AN/A$3.42 per shareN/A
Rallybio Co. stock logo
RLYB
Rallybio
$848K15.70N/AN/A$2.81 per share0.11
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$40.22M-$0.91N/AN/AN/AN/A-65.75%-52.71%8/12/2025 (Estimated)
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$66.86M-$0.99N/AN/AN/AN/A-18.01%-17.38%8/4/2025 (Estimated)
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
-$100.70M-$1.87N/AN/AN/AN/A-44.54%-40.72%8/11/2025 (Estimated)
Rallybio Co. stock logo
RLYB
Rallybio
-$74.56M-$1.09N/AN/AN/AN/A-77.39%-69.33%8/14/2025 (Estimated)

Latest RLYB, ATAI, DSGN, and ORIC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.19-$0.15+$0.04-$0.15N/A$1.56 million
5/14/2025Q1 2025
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.28-$0.31-$0.03-$0.31N/AN/A
5/8/2025Q1 2025
Rallybio Co. stock logo
RLYB
Rallybio
-$0.21-$0.21N/A-$0.21N/A$0.21 million
5/5/2025Q1 2025
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
-$0.51-$0.42+$0.09-$0.42N/AN/A
3/17/2025Q4 2024
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
-$0.14-$0.24-$0.10-$0.24$0.30 million($0.01) million
3/13/2025Q4 2024
Rallybio Co. stock logo
RLYB
Rallybio
-$0.27-$0.25+$0.02-$0.25$0.15 million$0.04 million
3/10/2025Q4 2024
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
-$0.28-$0.24+$0.04-$0.24N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
N/AN/AN/AN/AN/A
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/AN/AN/AN/AN/A
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
N/AN/AN/AN/AN/A
Rallybio Co. stock logo
RLYB
Rallybio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
0.14
5.81
5.81
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
N/A
34.61
34.61
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
N/A
10.56
13.15
Rallybio Co. stock logo
RLYB
Rallybio
N/A
9.55
9.55

Institutional Ownership

CompanyInstitutional Ownership
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
28.41%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
56.64%
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
95.05%
Rallybio Co. stock logo
RLYB
Rallybio
90.34%

Insider Ownership

CompanyInsider Ownership
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
31.20%
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
31.20%
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
6.82%
Rallybio Co. stock logo
RLYB
Rallybio
8.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Atai Life Sciences stock logo
ATAI
Atai Life Sciences
80200.34 million115.45 millionOptionable
Design Therapeutics, Inc. stock logo
DSGN
Design Therapeutics
4056.77 million38.96 millionOptionable
ORIC Pharmaceuticals, Inc. stock logo
ORIC
ORIC Pharmaceuticals
8071.09 million67.09 millionOptionable
Rallybio Co. stock logo
RLYB
Rallybio
4041.61 million38.42 millionNot Optionable

Recent News About These Companies

Rallybio downgraded to Hold from Buy at JonesResearch
Rallybio downgraded to In Line from Outperform at Evercore ISI
Rallybio (RLYB) was downgraded to a Hold Rating at H.C. Wainwright
Rallybio discontinues RLYB212 program
Citizens JMP downgrades Rallybio on RLYB212 discontinuation
JMP Securities downgrades Rallybio (RLYB) to a Hold
Rallybio reports Q4 EPS (25c), consensus (30c)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Atai Life Sciences stock logo

Atai Life Sciences NASDAQ:ATAI

$2.21 +0.15 (+7.28%)
Closing price 04:00 PM Eastern
Extended Trading
$2.19 -0.02 (-0.68%)
As of 06:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Design Therapeutics stock logo

Design Therapeutics NASDAQ:DSGN

$3.88 +0.07 (+1.84%)
Closing price 04:00 PM Eastern
Extended Trading
$3.87 -0.01 (-0.36%)
As of 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

ORIC Pharmaceuticals stock logo

ORIC Pharmaceuticals NASDAQ:ORIC

$5.78 -0.57 (-8.98%)
Closing price 04:00 PM Eastern
Extended Trading
$5.86 +0.08 (+1.37%)
As of 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Rallybio stock logo

Rallybio NASDAQ:RLYB

$0.32 -0.01 (-2.82%)
Closing price 04:00 PM Eastern
Extended Trading
$0.33 +0.01 (+3.75%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.